Currently, precise breast cancer treatment according to molecular subtypes, which are determined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and Ki67 status, is highly recommended by the oncological community[2]. This evidence concerns the gene ESR1 and breast carcinoma.